Hyperparathyroidism Medical Services in China

Hyperparathyroidism is an endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to dysregulated calcium and phosphorus metabolism. It is broadly classified into primary, secondary, and tertiary forms. Primary hyperparathyroidism (PHPT), the most common type, results from autonomous PTH overproduction—typically due to a single parathyroid adenoma (85–90%), less commonly hyperplasia (10–15%), or rarely carcinoma (<1%). Secondary hyperparathyroidism arises as a compensatory response to chronic hypocalcemia, most often driven by chronic kidney disease (CKD) or vitamin D deficiency. Tertiary hyperparathyroidism occurs when long-standing secondary disease leads to irreversible parathyroid gland autonomy, frequently seen in advanced CKD patients post-kidney transplant. Pathophysiologically, elevated PTH increases bone resorption, renal calcium reabsorption, and intestinal calcium absorption (via upregulation of renal 1α-hydroxylase and subsequent calcitriol synthesis), resulting in hypercalcemia, hypophosphatemia, and increased urinary calcium excretion. Epidemiologically, PHPT affects approximately 0.1–0.3% of the general population, with incidence rising sharply after age 50; women are affected two to three times more often than men. Risk factors include prior neck irradiation, genetic syndromes (e.g., MEN1, MEN2A, HRPT2 mutations), lithium therapy, and chronic kidney disease. Untreated or severe cases significantly impair quality of life: patients commonly report debilitating fatigue, cognitive fog, depression, muscle weakness, bone pain, recurrent nephrolithiasis, and gastrointestinal disturbances such as constipation and peptic ulcer disease. Osteoporosis and vertebral fractures increase fracture risk by 2–4 fold; cardiovascular complications—including hypertension, left ventricular hypertrophy, and vascular calcification—are also prevalent. Early diagnosis remains challenging, as up to 80% of newly diagnosed cases in high-resource settings are asymptomatic or minimally symptomatic, identified incidentally via routine serum calcium testing. Delayed management may lead to irreversible renal damage (nephrocalcinosis, chronic kidney disease progression) and skeletal demineralization. Importantly, even mild hypercalcemia correlates with measurable declines in physical functioning, sleep quality, and emotional well-being—underscoring the need for individualized assessment beyond biochemical thresholds alone.

Hyperparathyroidism is a disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to disturbances in calcium, phosphorus, and bone metabolism. It is classified into primary, secondary, tertiary, and ectopic forms, with primary hyperparathyroidism (PHPT) being the most common endocrine disorder after type 2 diabetes mellitus. The predominant cause of PHPT is a solitary parathyroid adenoma (80–85% of cases), followed by multiglandular hyperplasia (10–15%), parathyroid carcinoma (<1%), and double adenomas (rare). Adenomas arise from clonal proliferation of chief cells and are typically sporadic; however, they may occur in familial contexts. Parathyroid hyperplasia—diffuse or nodular—often underlies familial syndromes such as multiple endocrine neoplasia type 1 (MEN1), MEN2A, and hyperparathyroidism-jaw tumor syndrome (HPT-JT), implicating germline mutations in MEN1, RET, and CDC73 (HRPT2), respectively. CDC73 mutations confer markedly increased risk of parathyroid carcinoma and ossifying fibromas.

Triggers for biochemical decompensation or symptomatic presentation include acute volume depletion (e.g., dehydration, diuretic use), immobilization (especially prolonged bed rest), lithium therapy (which alters PTH set-point and promotes glandular hyperplasia), vitamin D deficiency (paradoxically exacerbating PTH secretion despite normocalcemia), and chronic kidney disease stage 3b or worse (in secondary forms). Lithium is a well-established pharmacologic trigger: long-term use (>1 year) increases PHPT prevalence 7- to 10-fold and is associated with higher rates of multiglandular disease. Acute illness, surgery, or metabolic stress may unmask latent hyperparathyroidism via shifts in calcium-binding proteins or acid-base balance.

Established risk factors include female sex (female-to-male ratio ~3:1), advancing age (peak incidence 50–70 years), prior neck irradiation (especially childhood exposure), and chronic kidney disease (CKD). CKD induces secondary hyperparathyroidism through phosphate retention, hypocalcemia, and impaired renal 1α-hydroxylation of vitamin D, resulting in reduced intestinal calcium absorption and compensatory PTH upregulation. Tertiary hyperparathyroidism emerges when autonomous PTH secretion persists after correction of the inciting stimulus (e.g., post-kidney transplant). Other modifiable risk factors include long-term proton pump inhibitor (PPI) use (associated with subtle hypocalcemia and elevated PTH in some cohorts), obesity (linked to low-grade inflammation and altered vitamin D metabolism), and dietary calcium restriction (which stimulates PTH release via calcium-sensing receptor [CaSR] signaling).

Genetic factors play a pivotal role in approximately 10% of PHPT cases. Autosomal dominant inheritance patterns are observed in MEN1 (menin gene), MEN2A (RET proto-oncogene), HPT-JT (CDC73), and familial isolated hyperparathyroidism (FIHP), which may represent phenotypic variants of the above or involve novel loci. Germline CaSR mutations cause autosomal dominant hypocalcemia with hypercalciuria—but loss-of-function variants can rarely present with atypical hyperparathyroidism. More recently, germline mutations in GNA11 and AP2S1 have been linked to familial hypocalciuric hypercalcemia (FHH) types 2 and 3, which mimic PHPT but require genetic differentiation due to divergent management. Genetic testing is recommended for patients diagnosed before age 45, those with multigland disease, recurrent or persistent disease, or personal/family history of associated tumors (e.g., pituitary adenomas, pancreatic neuroendocrine tumors, medullary thyroid cancer, renal cysts).

Environmental factors remain less definitively established but include ionizing radiation exposure (head/neck radiotherapy for Hodgkin lymphoma or thyroid cancer increases relative risk 2- to 4-fold), nutritional deficiencies (particularly chronic vitamin D insufficiency and suboptimal dietary calcium intake), and possibly air pollution-related systemic inflammation (emerging epidemiologic data suggest associations with dysregulated mineral metabolism). Socioeconomic determinants—including limited access to routine biochemical screening—contribute to delayed diagnosis and higher complication rates (e.g., nephrolithiasis, osteoporosis, cardiovascular calcification). Notably, geographic latitude influences vitamin D synthesis, and populations residing at higher latitudes demonstrate higher PHPT prevalence, likely mediated through chronic vitamin D deficiency and compensatory PTH elevation. While no direct causal link has been proven for endocrine-disrupting chemicals (e.g., bisphenol A, phthalates), experimental models suggest potential modulation of CaSR expression and parathyroid cell proliferation warranting further investigation.

Hyperparathyroidism is a disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to dysregulation of calcium, phosphorus, and bone metabolism. It is broadly classified into primary, secondary, and tertiary forms; however, when referring to classic clinical presentation without specified etiology, primary hyperparathyroidism (PHPT) is most commonly implied—particularly in endocrinology practice. Early symptoms are often subtle, nonspecific, and easily overlooked, contributing to frequent diagnostic delays. Patients may report persistent fatigue, mild cognitive complaints such as difficulty concentrating or 'brain fog', unexplained anxiety or low-grade depression, and generalized malaise. Sleep disturbances—including insomnia or nonrestorative sleep—are common early manifestations. Some individuals experience mild musculoskeletal discomfort, notably proximal muscle weakness (e.g., difficulty rising from a chair or climbing stairs) and vague joint aches without objective inflammation. Gastrointestinal symptoms may include intermittent constipation, early satiety, or nonspecific abdominal discomfort—often misattributed to irritable bowel syndrome or functional dyspepsia. Notably, up to 30–40% of patients with mild PHPT are entirely asymptomatic at diagnosis, identified incidentally through routine serum calcium screening.

Typical symptoms emerge as hypercalcemia progresses and PTH-mediated bone resorption intensifies. Sustained hypercalcemia (>10.5 mg/dL or >2.62 mmol/L) commonly manifests as polyuria and polydipsia due to calcium-induced nephrogenic diabetes insipidus—impaired renal concentrating ability resulting from downregulation of aquaporin-2 channels in collecting ducts. Nephrolithiasis is a hallmark feature: recurrent calcium oxalate or calcium phosphate kidney stones occur in approximately 15–20% of patients, often presenting with acute flank pain, hematuria, or urinary tract infection. Bone-related manifestations include osteopenia or osteoporosis—particularly at cortical-rich sites such as the distal radius and femoral neck—with increased fracture risk independent of BMD values. In advanced or long-standing cases, 'brown tumors' (osteoclastic giant cell lesions) may develop, though these are rare in contemporary practice. Neuromuscular symptoms become more pronounced: patients describe profound fatigue, lethargy, diminished exercise tolerance, and occasionally proximal myopathy confirmed by elevated creatine kinase (CK) in some cases. Gastrointestinal complications escalate to peptic ulcer disease (due to gastrin hypersecretion and increased gastric acid output), pancreatitis (hypercalcemia-induced trypsinogen activation), and anorexia with weight loss.

Accompanying symptoms reflect multisystem involvement. Cardiovascular findings include hypertension (prevalence ~50–70%), left ventricular hypertrophy, shortened QT interval on ECG, and increased arterial stiffness—partly attributable to vascular calcification and endothelial dysfunction. Dermatologic signs may include pruritus, especially in the setting of concomitant renal impairment. Patients frequently report subjective memory deficits, slowed processing speed, and emotional lability—neuropsychiatric features validated in prospective neuropsychological testing. Dry mouth and dental abnormalities (e.g., enamel hypoplasia, premature tooth loss) may occur, particularly in younger-onset or familial forms. Rarely, chondrocalcinosis (calcium pyrophosphate deposition disease) presents as pseudogout attacks.

Complications arise from chronic calcium and PTH excess. Renal complications include nephrocalcinosis, progressive chronic kidney disease (CKD), and end-stage renal disease—especially when hypercalcemia coexists with volume depletion or nephrotoxic medications. Skeletal complications encompass vertebral compression fractures, pathologic fractures, and severe osteitis fibrosa cystica (now uncommon in developed countries). Cardiovascular morbidity includes accelerated atherosclerosis, coronary artery calcification, and increased risk of atrial fibrillation and heart failure. Neurocognitive decline may progress to dementia-like syndromes in untreated elderly patients. In pregnancy, maternal PHPT confers risks of fetal hyperparathyroidism, intrauterine growth restriction, and neonatal hypocalcemic tetany.

Diagnosis relies on biochemical confirmation: elevated intact PTH in the presence of hypercalcemia establishes PHPT. Serum calcium must be corrected for albumin (corrected calcium = measured calcium + 0.8 × [4.0 − albumin g/dL]) or preferably measured as ionized calcium. Concomitant hypophosphatemia supports the diagnosis; however, normophosphatemia does not exclude PHPT. Additional evaluation includes 25-hydroxyvitamin D (to assess for vitamin D insufficiency, which may exacerbate hyperparathyroidism), renal function (creatinine, eGFR), urinary calcium excretion (24-hour urine calcium-to-creatinine ratio helps differentiate PHPT from familial hypocalciuric hypercalcemia), and bone mineral density (dual-energy X-ray absorptiometry at lumbar spine, femoral neck, and distal radius). Imaging—such as sestamibi parathyroid scintigraphy, high-resolution neck ultrasound, or 4D-CT—is reserved for surgical planning after biochemical diagnosis is secured.

Differential diagnosis is critical. Familial hypocalciuric hypercalcemia (FHH), caused by inactivating CASR mutations, mimics PHPT but features low urinary calcium excretion (calcium/creatinine clearance ratio <0.01), normal or mildly elevated PTH, and autosomal dominant inheritance. Vitamin D intoxication presents with hypercalcemia and suppressed PTH—distinguished by history of supplementation and elevated 25(OH)D levels. Milk-alkali syndrome involves hypercalcemia, metabolic alkalosis, and renal impairment following excessive calcium carbonate intake. Granulomatous diseases (e.g., sarcoidosis, tuberculosis) cause extrarenal 1,25-dihydroxyvitamin D overproduction, resulting in hypercalcemia with suppressed PTH. Malignancy-associated hypercalcemia (e.g., multiple myeloma, squamous cell carcinoma) typically shows markedly elevated calcium, suppressed PTH, and evidence of underlying neoplasm (elevated SPEP, imaging abnormalities). Other considerations include lithium-induced hyperparathyroidism (chronic use alters PTH set-point), thyrotoxicosis (increased bone turnover), and adrenal insufficiency (rarely associated with mild hypercalcemia). Accurate differentiation guides management: surgical parathyroidectomy remains definitive therapy for symptomatic or guideline-indicated PHPT, whereas FHH and malignancy-associated hypercalcemia require entirely distinct approaches.

Hyperparathyroidism is a disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands, leading to disturbances in calcium, phosphorus, and bone metabolism. It is broadly classified into primary, secondary, and tertiary forms, with primary hyperparathyroidism (PHPT) being the most common endocrine disorder after type 2 diabetes. In PHPT, autonomous PTH overproduction results in hypercalcemia, hypophosphatemia, and increased bone resorption—often asymptomatic but potentially causing nephrolithiasis, osteoporosis, cognitive changes, fatigue, and cardiovascular complications. Management must be individualized based on disease severity, symptomatology, age, comorbidities, and biochemical profile.

Conservative treatment is appropriate for asymptomatic or minimally symptomatic patients meeting strict criteria: serum calcium no more than 1 mg/dL above the upper limit of normal; estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m²; no evidence of nephrocalcinosis, kidney stones, or vertebral fractures on imaging; and bone mineral density (BMD) T-score >−2.5 at lumbar spine, femoral neck, or distal radius. These patients require vigilant monitoring: serum calcium and creatinine every 6 months; annual BMD assessment via dual-energy X-ray absorptiometry (DXA); and periodic 24-hour urinary calcium excretion to assess stone risk. Lifestyle modifications include maintaining adequate hydration (≥2 L/day), restricting sodium intake (<2 g/day), avoiding thiazide diuretics and lithium, and ensuring moderate dietary calcium (1000–1200 mg/day)—neither deficient nor excessive—to prevent secondary hyperparathyroidism or exacerbation of hypercalciuria. Vitamin D repletion is encouraged only if serum 25-hydroxyvitamin D <20 ng/mL, targeting levels between 30–50 ng/mL, as deficiency may worsen PTH elevation without increasing hypercalcemia risk when managed appropriately.

Pharmacologic therapy serves adjunctive or bridging roles. Calcimimetics—specifically cinacalcet—are FDA- and NMPA-approved for PHPT in patients ineligible for surgery or with persistent/recurrent disease postoperatively. Cinacalcet allosterically enhances the calcium-sensing receptor’s sensitivity to extracellular calcium, thereby suppressing PTH secretion and lowering serum calcium. It is titrated starting at 30 mg once daily, up to 180 mg/day, with monitoring of serum calcium and magnesium. Adverse effects include nausea, vomiting, and hypocalcemia (requiring dose adjustment or supplementation). For bone protection, bisphosphonates (e.g., alendronate 70 mg weekly) are indicated in patients with osteoporosis or low BMD, though they do not correct hypercalcemia or reduce PTH. Denosumab, a RANK ligand inhibitor, may be considered in select cases with contraindications to bisphosphonates, but requires careful calcium/vitamin D repletion pre-initiation to avoid severe hypocalcemia. Hormone replacement therapy (HRT) is not recommended solely for hyperparathyroidism management due to unfavorable risk-benefit profiles in most populations.

Surgical intervention remains the only curative treatment for primary hyperparathyroidism. Parathyroidectomy—typically minimally invasive unilateral exploration guided by intraoperative PTH assay (IO-PTH)—achieves cure rates exceeding 95% in experienced centers. Preoperative localization using high-resolution ultrasound and sestamibi (99mTc-MIBI) scintigraphy is standard; 4D-CT and MRI are increasingly utilized for complex or reoperative cases. Intraoperative PTH monitoring confirms successful resection when levels drop ≥50% from baseline at 10 minutes post-excision. Bilateral neck exploration is reserved for multiglandular disease, familial syndromes (e.g., MEN1), or failed prior localization. Complications are rare in high-volume centers: transient hypocalcemia (up to 30%, usually self-limited), permanent hypoparathyroidism (<1%), recurrent laryngeal nerve injury (<0.3%), and hematoma (<0.5%). Surgery is strongly indicated for symptomatic disease, serum calcium >1 mg/dL above normal, creatinine clearance <60 mL/min, renal stones, reduced BMD, age <50 years, or inability to comply with surveillance.

Treatment advantages in China reflect rapid advancements in endocrine surgery, imaging, and multidisciplinary coordination. Major academic hospitals—including Peking Union Medical College Hospital, Shanghai Jiao Tong University Affiliated Ruijin Hospital, and West China Hospital—perform over 1,000 parathyroidectomies annually with standardized protocols endorsed by the Chinese Society of Endocrinology. High-resolution ultrasound is widely accessible and performed by endocrinologists trained in parathyroid mapping, reducing reliance on nuclear medicine. IO-PTH assays are routinely available in tier-3 hospitals, enabling real-time surgical decision-making. Moreover, China’s national health insurance covers cinacalcet and generic bisphosphonates, improving affordability. Telemedicine platforms facilitate longitudinal follow-up, especially for rural patients, while integrated electronic health records support seamless transitions between outpatient endocrinology, nuclear medicine, radiology, and surgery departments.

Post-treatment recovery emphasizes structured, evidence-based guidance. After parathyroidectomy, patients should monitor for perioral numbness, tingling, or muscle cramps—signs of hypocalcemia—and maintain oral calcium (1–2 g elemental calcium daily) and calcitriol (0.25–0.5 mcg/day) for 1–2 weeks, tapering based on serial calcium measurements. Hydration and early ambulation reduce thromboembolic risk. Patients resume normal activities within 3–5 days but avoid heavy lifting (>5 kg) for 10 days. Long-term follow-up includes serum calcium, creatinine, and PTH at 1, 3, 6, and 12 months post-op, then annually. BMD reassessment is recommended at 1–2 years. For medically managed patients, adherence to hydration, dietary sodium restriction, and scheduled monitoring is critical. Psychological support is advised, as fatigue and cognitive complaints often improve gradually over 3–6 months post-surgery. Finally, all patients—regardless of treatment modality—should receive education on recognizing hypercalcemic emergencies (e.g., confusion, polyuria, vomiting) and seeking urgent care. With timely, protocol-driven care, outcomes for hyperparathyroidism in China align closely with international benchmarks, underscoring the value of centralized expertise, technological integration, and patient-centered rehabilitation.